Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ene, I"'
Publikováno v:
Clinical Research & Regulatory Affairs. Sep2005, Vol. 22 Issue 3/4, p103-118. 16p.
Publikováno v:
Clinical Research & Regulatory Affairs. 2004, Vol. 21 Issue 2, p155-177. 23p.
Autor:
Tony Tramontin, Pravin Chaturvedi, Ene I. Ette, John Orloff, Navjot Singh, Gigi Hirsch, Donald R. Stanski, Howard L. Golub, Frank L. Douglas, Cyrus R. Mehta, Edd Fleming, Sameer Sabir, Susan Levinson, José Pinheiro, Paul Gallo, Nitin R. Patel, Stacy L. Springs, Matthias Evers, Michael Branson
Publikováno v:
Nature Reviews Drug Discovery. 8:949-957
Declining pharmaceutical industry productivity is well recognized by drug developers, regulatory authorities and patient groups. A key part of the problem is that clinical studies are increasingly expensive, driven by the rising costs of conducting P
Autor:
Paul J. Williams, Ene I. Ette
Publikováno v:
Annals of Pharmacotherapy. 38:1702-1706
OBJECTIVE To present and emphasize the background, foundations, utility, and conceptual underlying theory of the population pharmacokinetic (PPK) approach with an examination of the advantages when compared with other approaches of pharmacokinetic mo
Publikováno v:
Clinical Research and Regulatory Affairs. 21:155-177
Drug development is a complex process, and added to it is the sophisticated new technologies and approaches to drug design, of which rational drug design is the epitome. A low success rate for investigational new drugs calls for improvement in drug d
Publikováno v:
Clinical Research and Regulatory Affairs. 11:243-255
Serum concentrations of a drug under development were obtained from an animal pharmacokinetic study using the one sample per animal design, and analyzed using the population data analysis program, NONMEM. A two compartment open model with IV administ
Autor:
Ene I. Ette, Christopher J. Godfrey
Publikováno v:
Clinical Trial Simulations ISBN: 9781441974143
The application of pharmacometrics to knowledge acquisition adds value to the drug development process because it enables the translation of information about drug action and interaction with the disease process into knowledge by enabling quantitativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ecf59a6fc0d159915ce8bb2b129ed19
https://doi.org/10.1007/978-1-4419-7415-0_8
https://doi.org/10.1007/978-1-4419-7415-0_8
Autor:
Paul J. Williams, Ene I. Ette
Publikováno v:
Pharmacometrics: The Science of Quantitative Pharmacology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cc478a9c4ec56c604d2754a67284bd0
https://doi.org/10.1002/9780470087978.ch17
https://doi.org/10.1002/9780470087978.ch17
Autor:
Paul J. Williams, Ene I. Ette
Publikováno v:
Pharmacometrics
Drug development continues to be expensive, time consuming, and ineffi cient, while pharmacotherapy is often practiced at suboptimal levels of performance (1–3). This trend has not waned despite the fact that massive amounts of drug data are obtain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11af5a9cb0a27c1a214d863d1418146f
https://doi.org/10.1002/9780470087978.ch1
https://doi.org/10.1002/9780470087978.ch1
Publikováno v:
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics ISBN: 9781475753455
Drug development and clinical trial structure functions most efficiently when based on pharmacometric (PM) knowledge. PM knowledge comes from outstanding data, and when it is interpreted in light of development goals and other knowledge, then an unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33421c8ff069140661e27c3dd86a64c1
https://doi.org/10.1007/978-1-59259-734-5_11
https://doi.org/10.1007/978-1-59259-734-5_11